Powerful perspectives
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Press release
Peer-reviewed translational research paves the way for first-in-class autotaxin inhibitor IOA-289 in cancer
Press release
iOnctura expands pipeline and receives development grant from Health Holland and KWF
Press release
iOnctura awarded UK’s MHRA innovation passport for entry into innovative licensing and access pathway (ILAP)
Press release
iOnctura announces publication of pioneering research describing the unique biological features of roginolisib
Press release
iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program
Press release
iOnctura awarded EUR17.5 million funding from the EIC accelerator for clinical development of novel pancreatic cancer therapy
Press release
iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289
Press release
iOnctura expands Advisory Board
Press release
iOnctura to present at ASCO IOA-244 showing highly promising impact on overall survival for patients with metastatic and refractory uveal melanoma
Press release
iOnctura to present at ASCO encouraging Phase Ib refractory uveal melanoma data for first semi-allosteric PI3Kδ inhibitor, IOA-244
Press release
iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289
Press release
iOnctura to present preclinical data on its clinical stage autotaxin inhibitor, IOA-289, at AACR
Looking for media
resources?